Editorial Policies

Aims and Scope

The journal “Annals of Clinical and Experimental Neurology” (Annaly klinicheskoy i eksperimental’noy nevrologii) is a peer-review medical journal, which provides articles for practicing neurologists, neurosurgeons, cardiologists, critical care and neurorehabilitation professionals, neuropsychologists, neuroradiologists, clinical neurophysiologists, as well as neuroscience professionals.

Annals of clinical and experimental neurology publishes articles on different aspects of diseases of the central and peripheral nervous system, different topics in neuroscience, historical neurology and neuroscience, as well as on related medical specialities.

The journal’s unique mission is to cover current problems and modern achievements in the field of neurology, neurosurgery, critical care, neurorehabilitation, neuroimaging, cardioneurology, clinical neurophysiology, fundamental neuroscience as well as to contribute to the formation of new promising research and training of highly qualified personnel in these areas.

Journal’s main tasks are:

  • Reflection of the results of scientific research in the most significant areas of neurology and related neuroscience.
  • Regular informing of the medical community about the latest achievements and prospects for the development of domestic and foreign medical science in the field of neurology.
  • Promoting the widespread introduction into practice of the latest achievements of neuroscience.
  • Creation of a platform for an exchange of views on the most significant problems of clinical and fundamental neuroscience, professional development and knowledge level of specialists.


Peer Review Process

All articles submitted to the journal are ongoing the following peer-review procedure.

1. Registration and checking for plagiarism
First, we register and evaluate manuscripts for compliance with the guidelines for authors and investigater the conflict of interest form. Every manuscript is checked using Antiplagiat software for plagiarisms detection. In case of plagiarism detecting the article is no further processed.

2. Review by the editor-in-chief and vice editors-in-chief
Initially all submitted manuscripts are reviewed by the Editor-in-Chief or one of the Associate Editors. Editors evaluate the compliance of the manuscript with the journal aims and scope, its value for the scientific literature and assigns reviewers if the deicision is positive. After this (usually up to 2 week), the corresponding author receives a message that the article is assigned to the peer-review procedure or rejected. If the manuscript is rejected the corresponding author explanations are also provided.

3. Statistical methods review
All original papers are reviewed for statistical methods by a medical statistics expert. Statistical methods review is carried out in addition to the peer review.

4. Peer-review
All articles undergo a single blind peer-review. Reviewing manuscripts is confidential in relation to the reviewers (ie, the author does not know who the reviewer). Disclosure of the confidential details of the manuscript review will be considered as violation of the authors and reviewer rights. Breach of confidentiality is only possible in case of declaration of data inaccuracy or falsification.

Peer reviewers are chosen among the members of the editorial board or editorial council. According to the Editor-in-Chief decision other expert consultants may also be involved in the peer-review. The peer review can not be provided by an author (co-author) of the manuscript. The peer reviewers are responsible to prevent the publication of articles containing violations of scientific ethics and serious deviations from Good Publication Practice.

The duration of the peer review procedure usually does not exceed 3 weeks. The period from the date of registration to the final decision date is usually not more than 4 months.

Peer reviewers will consider following aspects when reviewing the manuscript:
1. Whether the content of the article complies to the title;
2. Clarity of presentation (language, style, order of data presentation, tables, figures, formulas etc.)
3. Suitability methods and originality of obtained results.
4. Describe the scientific value of the manuscript and articles disadvantages
5. Which corrections and additions are necessary

Peer reviewers fill out the form of review which highlights all the most important aspects of the review.

The reviewer takes a decision on the possibility of publication:

  • Accept
  • Accept after correction
  • Revise and resubmit
  • Reject

At the end manuscript analysis the peer reviewer gives final recommendations. If some corrections should be done, the article is sent to the authors for revision. The manuscript should be revised and returned within 1 month. If the manuscript is returned later the date of its publication will be changed. Resubmitted articles undergo additional peer review. The peer reviewer takes a decision on the possibility of its publication.

The presence of positive reviews is not sufficient for the publication of the manuscript. The final decision on whether the publication is accepted is taken by the Editorial Board. The Editorial Board reserves the right to reduce and update manuscripts.

5. Manuscript acceptance and rejection
If the editorial board accepted the manuscript for publication the technical secretary informs the corresponding author. If the manuscpript is rejected the authors will receive comments on the decision. Rejected manuscripts can not be resubmitted. Negative reviews are sent to the corresponding author by e-mail.

6. Appeals
If authors disagree with the editorial board decision , they have a right to appeal. The appeal can be submitted only once. All appeals are considered by the editorial board. The revision of an appeal usually takes 1-2 months.

Additional Information
1. The editorial board provides manuscripts peer reviews per request to the Higher Attestation Commission.
2. The editors do not provide any information concerning the reviewes manuscript at anyone except the authors and editorial office staff. Reviewers are not allowed to make copies of the manuscript or pass any parts of the manuscript for review to another person without the permission of the editors. Peer reviewers and editorial office staff are not allowed to use the content of the manuscript in their own interests before publication.
3. If the publication of the article has caused violation of someone else’s copyright, or Good Publication Practice, the Editorial Board has the right to withdraw the published article.


Publication Frequency

The journal publish issues quarterly (4 times a year).


Open Access Policy

The publications in the Journal are available to all interested from the moment of publication. So, this journal provides immediate Platinum Open Access (in accordance with Budapest Open Access Initiative) to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Also the editorial board belives that it provides free public access to the results of research and contributes to the advancement of science and medicine.

Free Full-text access to all articles can be observed via journal's website. All accepted articles publish with the Creative Commons Attribution International license (CC BY) for more freely distribution and usage worlwide.



The journal uses the PKP Preservation Network (PKP PN) to digitally preserve all the published articles. The PKP PN is a part of LOCKSS (Lots of Copies Keep Stuff Safe) program offers decentralized and distributed preservation, seamless perpetual access, and preservation of the authentic original version of the content.

Also, the journal makes full-text archives on Russain State Library and on Russian Science Electronic Library (http://elibrary.ru/) platform.





The journal is indexed in the following international databases and directory editions:

  • Russian Science Citation Index (RSCI) on Web of Science
  • Russian Index of Scientific Citation (eLibrary.ru)
  • Google scholar
  • WorldCat


Publication Ethics Policy

The Ethics policy of "Annals of Clinical and Experimental Neurology" is based on recomendations from international commettees:

Reporting standarts

The Annals of Clinical and Experimental Neurology journal editorial team ask authors of reports of original research to present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.

Data Access and Retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines (based on ICMJE guidelines):

All authors whose names appear on the submission:

  1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work AND
  2. drafted the work or revised it critically for important intellectual content AND
  3. approved the version to be published AND
  4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.

Submissions by anyone other than one of the authors will not be considered.

Research Ethics and Patient Consent (Statement of Human and Animal Rights)

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

Hazards for Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Research involving human embryos, gametes, and stem cells

Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals)

The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent (See also Informed consent) was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Copies of approval and redacted consent documents may be requested by the Journal.

We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.

In deciding whether to publish papers describing modifications of the human germline, the Journal is guided by safety considerations, compliance with applicable regulations, as well as the status of the societal debate on the implications of such modifications for future generations. In case of concerns regarding a particular type of study the Journal may seek the advice from the Springer Nature Research Integrity Group.

The decision to publish a paper is the responsibility of the Editor-in-Chief of the Journal.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Conflicts of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Conflicts include the following:

  • Financial — funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work;
  • Affiliations — being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work;
  • Intellectual property — patents or trademarks owned by someone or their organization;
  • Personal — friends, family, relationships, and other close personal connections;
  • Ideology — beliefs or activism, for example, political or religious, relevant to the work;
  • Academic — competitors or someone whose work is critiqued.

For more information on conflicts of interest, see the guidance from the ICMJE and WAME.

Funding and Acknowledgement of Sources

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/  

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.


Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Only original works are acceptable for publication in "Annals of Clinical and Experimental Neurology". The journal does not allow any forms of plagiarism. Authors must not use the words, figures, or ideas of others without attribution. All sources must be cited at Annals of Clinical and Experimental Neurology take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. All the submitted articles are evaluated with plagiarism-checking software (Antiplagiat). Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to:

  • publishing an erratum or corrigendum (correction);
  • retracting the article;
  • taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies;
  • or taking appropriate legal action.

Also you can see ORI Avoiding Plagiarism, Self-plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing

Duplicate Submission and Redundant Publication

Annals of Clinical and Experimental Neurology consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.

Manuscripts submitted to Annals of Clinical and Experimental Neurology must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.

If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.

Annals of Clinical and Experimental Neurology will consider extended versions of articles published at conferences provided this is declared in the cover letter, the previous version is clearly cited and discussed, there is significant new content, and any necessary permissions are obtained.

Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.

Citation Manipulation

Authors whose submitted manuscripts are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, may incur sanctions.

Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.

Fundamental errors in published works, Corrections and Retractions

When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s). 

Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum (see more).

If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice. 

The journal use the CrossMark technology (by Crossref) to work with Corrections, Retractions and Editorial expressions of concern for Please, see the details on the CrossMark Policy.


If Annals of Clinical and Experimental Neurology becomes aware of breaches of our publication ethics policies, the following sanctions may be applied:

  • Rejection of the manuscript and any other manuscripts submitted by the author(s).
  • Not allowing submission for 1–3 years.
  • Prohibition from acting as an editor or reviewer.

Annals of Clinical and Experimental Neurology may apply additional sanctions for severe ethical violations.

General duties and responsibilities of editors

Editors are accountable for everything published in their journals:  Editors strive to meet the needs of readers and author and to constantly improve their journal; editors have processes in place to assure the quality of the material they publish; editors preclude business needs from compromising intellectual and ethical standards; editors will always be willing to publish corrections, clarifications, retractions and apologies when needed.

Relations with readers

Readers are always informed about who has funded research or other scholarly work and whether the funders had any role in the research and its publication and, if so, what this was.

Relations with authors

3.1. Editors’ decisions to accept or reject a paper for publication is based on the paper’s importance, originality and clarity, and the study’s validity and its relevance to the remit of the journal.
3.2. Editors do not reverse decisions to accept submissions unless serious problems are identified with the submission.
3.3. A description of peer review processes is published. In case of any important deviation from the described processes editors should be ready to justify any important deviation from the described processes.
3.4. A declared mechanism for authors to appeal against editorial decisions is available for authors.
3.5. A guidance to authors is published and regularly updated.
3.6. Сriteria for authorship are provided in “Guidance for authors”.

Relations with reviewers

Editors provide guidance to reviewers on everything that is expected of them including the need to handle submitted material in confidence. This guidance should be regularly updated and should refer or link to this code. Editors require reviewers to disclose any potential competing interests before agreeing to review a submission. Editors have systems to ensure that peer reviewers’ identities are protected.

Relations with editorial board members

Editors provide new editorial board members with guidelines on everything that is expected of them and keep existing members updated on new policies and developments.

Relations with journal owners and publishers

The relationship of editors to publishers is based on the principle of editorial independence. Editors make decisions on which articles to publish based on quality and suitability for the journal and without interference from the journal publisher.

Editorial and peer review processes

Editors strive to ensure that peer review at their journal is fair, unbiased and timely. Editors have systems to ensure that material submitted to their journal remains confidential while under review.

Protecting individual data

Editors must obey laws on confidentiality in their own jurisdiction. Regardless of local statutes, however, they should always protect the confidentiality of individual information obtained in the course of research or professional interactions (e.g. between doctors and patients). It is therefore almost always necessary to obtain written informed consent for publication from people who might recognise themselves or be identified by others (e.g. from case reports or photographs).

Encouraging ethical research (e.g. research involving humans or animals)

Editors ensure that research they publish was carried out according to the relevant internationally accepted guidelines (e.g. the Declaration of Helsinki for clinical research, the AERA and BERA guidelines for educational research). Editors seek assurances that all research has been approved by an appropriate body (e.g. research ethics committee, institutional review board) where one exists.

Dealing with possible misconduct

Editors have a duty to act if they suspect misconduct or if an allegation of misconduct is brought to them. This duty extends to both published and unpublished papers. Editors will first seek a response from those suspected of misconduct. If they are not satisfied with the response, they will ask the relevant employers, or institution, or some appropriate body (perhaps a regulatory body or national research integrity organization) to investigate.

Ensuring the integrity of the academic record

Errors, inaccurate or misleading statements must be corrected promptly and with due prominence.

Intellectual property

Editors work with their publisher to handle potential breaches of intellectual property laws and conventions.

Encouraging debate

Editors will consider cogent criticisms of work published in their journal. Authors of criticised material will be given the opportunity to respond.


Authors self-archiving

The journal is compliant with Platinum Open Access mode for articles distribution.

Terms and definitions

We use the following terms and definitions:

  • Preprint: An early version of an article prior to the version submitted for publication in a journal. Theses and dissertations are considered to be preprints.
  • SMUR (Submitted Manuscript Under Review): The version of the article that is under formal review for inclusion in the journal.
  • AM (Accepted Manuscript): The version of the article that has been accepted for publication. This version may include revisions resulting from peer review but may be subject to further modification by the Publisher (for example, copyediting and typesetting).
  • VoR (Version of Record): The version that is formally published. This not includes any Online First article that is formally identified as being published online before the compilation of a journal issue. The VoR includes any post-publication corrections.
  • Personal webpage: Web pages created by you, about you and your research which are hosted on a non-commercial website (such as your institute’s website). Personal profile pages in commercial sharing sites (such as ResearchGate, Academia.edu and Facebook) are not considered to be personal web pages.
  • Department or institutional repository: Web pages hosted by an academic or research institute or department to provide access to the work to promote and the activities of the institute or department, at all times operating for a non-commercial purpose.
  • Subject repository: Web pages hosted by an organization to provide access to the work from researchers working in a subject or range of subjects, at all times operating for a non-commercial purpose.
  • Commercial and non-commercialCommercial means any activity for direct or indirect financial gain. When considering whether a use is commercial or non-commercial, we look at the nature of the activity rather than the nature of the site or organization performing the activity.

What can be self-archived, where and when



web page

Department or institutional repository

Non-commercial subject repository
(e.g. PubMed Central)

Commercial repository or social media site
(e.g. ResearchGate, Academia.edu, SSRN)


At any time

At any time

At any time

At any time


At any time

At any time

At any time

At any time


At any time

At any time

At any time

At any time

Plan S compliance

Our Platinum OA policy is compatible with Plan S, and our License to Publish agreements with authors are not conflict with authors' agreements with their cOAlition S funders. 

Creative Commons and other end-user licenses

Preprints and SMURs can be made publicly accessible under any license terms the authors choose. We recommend a Creative Commons CC-BY or a more restrictive CC license.

Accepted Manuscripts can be made accessible under a Creative Commons CC-BY license or equivalent. 

Third-party material

Before posting articles online, authors should ensure they have the appropriate permission to include any third party content. When posting articles under a Creative Commons license, the permission should allow the third-party material to be included either (i) under the Creative Commons license or (ii) clearly indicated as being protected by third party copyright, with a clear notice that it cannot be reused without further permissions clearance from the identified third-party rights holder.

Closed deposits and embargo periods

Articles can be deposited in repositories before publication provided the content is only accessible to repository administration staff. This is sometimes referred to as ‘closed deposit’.

Metadata about the article (for example the article title, abstract, and journal citation) can be made public as soon as the article is published. The full text must not be made public before the embargo ends.

Any applicable embargo period starts from the date the Version of Record is first published online as part of a journal’s issue.

Posting content in repositories

We require repositories to include:

  • If an article has not yet been published, a clear statement that the material has been accepted for publication in a revised form, with a link to the journal’s site on https://annaly-nevrologii.com/.
  • For all published articles, a link to the article’s Version of Record in https://annaly-nevrologii.com/ – for example, via a DOI-based link.
  • A clear statement about the license terms under which the posted version of the article is deposited.

Example statements are:

  • This article has been published in a revised form in Annals of Clinical and Experimental Neurology [http://doi.org/XXX]. This version is free to view and download. © copyright holder.
  • This article has been published in a revised form in Annals of Clinical and Experimental Neurology [http://doi.org/XXX]. This version is published under a Creative Commons CC-BY. © copyright holder.

Citing content in repositories

When citing an Accepted Manuscript or an earlier version of an article, we request that readers also cite the Version of Record with a DOI link, for example: Subsequently published in revised form in Annals of Clinical and Experimental Neurology [http://doi.org/XXX].


Advertising and Reprints Policies

Our advertising policy is consistent with the principles mentioned in the Recommendations on Publication Ethics Policies for Medical Journals which issued by the World Association of Medical Editors (WAME).


  1. Annals of Clinical and Experimental Neurology and it's Publisher (Research Center of Neurology) generate revenue from advertising, which creates a potential conflict of interest. Editors’ decisions do not depend on the cost of advertising or producing reprints. Advertisers and sponsors have no influence over the editor’s decisions, regardless of the terms of advertising or other agreements.
  2. All advertisements are subject to the approval of the Annals of Clinical and Experimental Neurology editorial team and Publisher's staff, which reserves the right to reject or cancel any advertisement at any time.
  3. The functions of Annals of Clinical and Experimental Neurology editors and Publisher's advertising managers are separate.
  4. In the Annals of Clinical and Experimental Neurology professional (physician-directed) publications and web site, the intentional placement of advertising adjacent to articles discussing the company or product that is the subject of the advertisement is prohibited. Advertising content must be distinguished from editorial and other materials so that the difference between them is obvious.
  5. Publisher will not publish “advertorial” content in Annals of Clinical and Experimental Neurology, and sponsored supplements must be clearly indicated as such. If a supplement did not undergo peer review or underwent a peer review-process different from the rest of the journal that should be explicitly stated.
  6. The Annals of Clinical and Experimental Neurology editorial team have the right to refuse any advertisement that, in its sole discretion, is incompatible with its mission or inconsistent with the values of members, the publication/web site or the organization as a whole, and to stop accepting any advertisement previously accepted. Advertisements are subject to review by the editors of the Annals of Clinical and Experimental Neurology and Publisher's stuff. In no case shall separate agreements with Publisher or its subsidiaries supersede this policy.
  7. Once an advertisement has been deployed online, it will be withdrawn from the journal site at any time if the Editor(s)-in-Chief or Publisher's staff request its removal.
  8. Advertising for the following categories is prohibited:
    • Alcohol
    • Tobacco
    • Weapons, firearms, ammunition
    • Fireworks
    • Gambling and lottery
    • Pornography or related themes
    • Political and religious advertisements
    • Advertisements that claim to have a “miracle” cure or method
    • Advertisements that make unsubstantiated health claims for the products advertised
    • Advertisements directed at children
  9. Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered. Exaggerated or extravagantly worded copy will not be allowed. Advertisements will not be accepted if they appear to be indecent or offensive in either text or artwork, or if they relate to content of a personal, racial, ethnic, sexual orientation, or religious nature.
  10. All advertisements are accepted and published in Annals of Clinical and Experimental Neurology on the warranty of the advertisement agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.
  11. In consideration of publication of an advertisement, the advertiser and the advertisement agency, jointly and severally, agree to indemnify and hold harmless Publisher, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement, or plagiarism.
  12. Any references to Annals of Clinical and Experimental Neurology and Publisher or its products or services in advertisements, promotional material, or merchandising by the advertiser or agency is subject to Publisher’s written approval for such use.
  13. All advertisements for drug-specific campaigns must comply with the relevant Russian legislation that regulates advertising. Advertisers should make available to Publisher the marketing authorization and summary of product characteristics when submitting their advertisement. In the case of drug advertisements, proprietary names of pharmaceutical products must be accompanied by the chemical, generic, or official name; the quantity of all active substances must be stated along with the recommended dosage. Each page of an advertisement for a prescription-only medicine should be clearly labeled as intended for health professionals.
  14. Advertisements for products not approved by the FDA or the Ministry of Health of Russian Federation that make any kind of health claims must carry the following disclaimer: “These statements have not been evaluated by the Food and Drug Administration and/or the Ministry of Health of Russian Federation. This product is not intended to diagnose, treat, cure or prevent any disease.”
  15. While Pubisher welcomes and encourages information-rich advertising in Annals of Clinical and Experimental Neurology, advertisements, advertising icons and advertiser logos must be clearly distinguishable from editorial content and may require special labeling to distinguish them as such. All advertisements must clearly and prominently identify the advertiser by trademark or signature.
  16. Reprints should be published only in the form in which they were originally published in the journal (including subsequent corrections), so there should be no additions or changes in them.
  17. Publisher is not responsible for incidental or consequential damage for errors in displaying or printing an advertisement.
  18. Advertisements may not imply endorsement by the Annals of Clinical and Experimental Neurology or its publications/web site except as may be provided for under a separate agreement — in which case advertising must be pre-approved to ensure adherence to the letter and spirit of that separate agreement.
  19. The full rules for any market research or promotion associated with an advertisement must be displayed in the advertisement or available via a prominent link.
  20. The following online advertising formats are prohibited:
    • Pop-ups and floating advertisements.
    • Advertisements that collect personally identifiable information from visitors without their knowledge or permission.
    • Advertisements that extend across or down the page without the visitor having clicked or rolled-over the advertisement.
    • Advertisements that send visitors to another site without the visitor having clicked the advertisement.

Annals of Clinical and Experimental Neurology published advertising policies are not exhaustive and are subject to change at any time without notice.

We partner with third-party advertising companies to serve ads and/or collect certain information when you visit our website. These companies may use cookies or web beacons to collect non-personally identifiable information [not including your name, address, email address or telephone number] during your visit to this website to help show advertisements on other websites also likely to be of interest to you.

For contact with the Advertisement department of the Publisher, please, follow the link https://annaly-nevrologii.com/journal/pathID/about/journalSponsorship 


Publication Fees

Publication in Annals of Clinical and Experimental Neurology is free of charge for all authors.

The Annals of Clinical and Experimental Neurology charge no obligatory publication fees from authors - including those of peer-review management, manuscript processing, journal production, online hosting and archiving, Open Access.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies